StockUS listing USSPHRFOTCQBHealthcareStructurally Challenged

Starpharma Holdings Limited(SPHRF) Stock Analysis | Healthcare

USD --+0.00%
Reward38Moderate
Risk31Moderate
75%Data
Thin -22% profit margin · Revenue growing 360% YoY
USD —+0.00 (+0.00%) Previous close · OTCQB
Market cap 134.37M
Reward Ratingⓘ38 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ31 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SPHRF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Starpharma Holdings Limited?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.

AI Brief Pro

The brief on Starpharma Holdings Limited

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Starpharma Holdings Limited?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 134.37M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap134.37M
Beta0.487
Insider Activity
12M windowNo data
No insider activity data available for this ticker.